WO2014143807A3 - Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders - Google Patents
Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders Download PDFInfo
- Publication number
- WO2014143807A3 WO2014143807A3 PCT/US2014/027935 US2014027935W WO2014143807A3 WO 2014143807 A3 WO2014143807 A3 WO 2014143807A3 US 2014027935 W US2014027935 W US 2014027935W WO 2014143807 A3 WO2014143807 A3 WO 2014143807A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- pathway antagonist
- bcr pathway
- disorders
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention provides methods of treating a patient with a B-cell malignancy or disorder comprising administering an anti-CD37 antibody or antibody fragment in combination with a BCR pathway antagonist such as a SYK inhibitor, a BTK inhibitor or a CXCR4 antagonist. In one embodiment, the invention provides methods for B-cell reduction comprising contacting B-cells with an anti-CD37 antibody or antibody fragment and a BCR pathway antagonist. The invention includes compositions and kits comprising anti-CD37 antibody and antibody fragments for use in combination with a BCR pathway antagonist.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361801494P | 2013-03-15 | 2013-03-15 | |
US61/801,494 | 2013-03-15 | ||
US201361820540P | 2013-05-07 | 2013-05-07 | |
US61/820,540 | 2013-05-07 | ||
US201361913144P | 2013-12-06 | 2013-12-06 | |
US61/913,144 | 2013-12-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014143807A2 WO2014143807A2 (en) | 2014-09-18 |
WO2014143807A3 true WO2014143807A3 (en) | 2014-12-18 |
Family
ID=51538275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/027935 WO2014143807A2 (en) | 2013-03-15 | 2014-03-14 | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014143807A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ602176A (en) | 2010-03-12 | 2015-01-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
KR20140031883A (en) | 2011-04-01 | 2014-03-13 | 이뮤노젠 아이엔씨 | Cd37-binding molecules and immunoconjugates thereof |
MX342983B (en) | 2011-07-19 | 2016-10-19 | Merck Sharp & Dohme | 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors. |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
EA201691169A1 (en) | 2013-12-05 | 2016-09-30 | Асерта Фарма Б.В. | THERAPEUTIC COMBINATION OF PI3K INHIBITOR AND BTK INHIBITOR |
US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
CN105017256A (en) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | Polyfluorinated compound Bruton tyrosine kinase inhibitor |
WO2015193740A2 (en) | 2014-06-17 | 2015-12-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor |
HRP20211813T1 (en) | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
WO2016090255A1 (en) * | 2014-12-05 | 2016-06-09 | Sriram Balasubramanian | Biological markers for predicting responsiveness to ibrutinib and r-chop combination therapy and methods of using the same |
ES2764840T3 (en) * | 2015-01-28 | 2020-06-04 | Univ Bordeaux | Use of plerixafor to treat and / or prevent acute exacerbations of chronic obstructive pulmonary disease |
JP6444486B2 (en) * | 2015-02-05 | 2018-12-26 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | Multivalent CD20 binding molecules comprising Shiga toxin A subunit effector region and their enhanced compositions |
US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
CN106146508A (en) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | The drug combination optimized and treatment cancer and the purposes of autoimmune disease thereof |
WO2016167236A1 (en) | 2015-04-13 | 2016-10-20 | 第一三共株式会社 | Treatment method combining mdm2 inhibitor and btk inhibitor |
EP3302561A4 (en) * | 2015-06-08 | 2019-02-06 | Debiopharm International SA | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
PT3954690T (en) | 2015-07-02 | 2023-06-06 | Acerta Pharma Bv | Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
WO2017040247A1 (en) | 2015-08-28 | 2017-03-09 | Immunogen, Inc. | Antibodies and assays for detection of cd37 |
EA201890613A1 (en) | 2015-09-21 | 2018-10-31 | Аптево Рисёрч Энд Девелопмент Ллс | POLYPEPTIDES CONNECTING CD3 |
CA3037688A1 (en) | 2016-09-21 | 2018-03-29 | Aptevo Research And Development Llc | Cd123 binding proteins and related compositions and methods |
US11278629B2 (en) * | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
TW201922256A (en) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | Methods for treating lymphoid malignancies |
WO2024138144A1 (en) * | 2022-12-22 | 2024-06-27 | The Medical College Of Wisconsin, Inc. | Compositions that target cd138 and cd3 and methods of making and using the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080279850A1 (en) * | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
-
2014
- 2014-03-14 WO PCT/US2014/027935 patent/WO2014143807A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080279850A1 (en) * | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
Non-Patent Citations (2)
Title |
---|
LU ET AL.: "Therapeutic advancement of chronic lymphocytic leukemia.", J HEMATOL ONCOL, vol. 5, 16 September 2012 (2012-09-16), pages 12PP * |
VLAD ET AL.: "Down-regulation of CXCR4 and CD 62L in chronic lymphocytic leukemia cells is triggered by B- cell receptor ligation and associated with progressive disease.", CANCER RES, vol. 69, no. 16, 15 August 2009 (2009-08-15), pages 6387 - 6395 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014143807A2 (en) | 2014-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014143807A3 (en) | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders | |
WO2015116729A3 (en) | Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders | |
MA39906A (en) | Combination therapies for the treatment of cancer | |
MX2016015181A (en) | Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer. | |
MX2021008113A (en) | Methods for treating or preventing asthma by administering an il-4r antagonist. | |
HK1213925A1 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer 18.2 | |
MX2016013218A (en) | Trifunctional antigen-binding molecule. | |
MX2016004736A (en) | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody. | |
MX2015002947A (en) | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor. | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
MX2016002645A (en) | Combination therapy for the treatment of glioblastoma. | |
EA201490194A1 (en) | COMBINED THERAPY, INCLUDING CDK4 / 6 INHIBITOR AND PI3K INHIBITOR FOR USE IN CANCER TREATMENT | |
PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
WO2016066634A3 (en) | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer | |
BR112017023517A2 (en) | anti-cd20 antibody for cancer treatment, pharmaceutical composition, method of treating a cancer patient and use of an anti-cd20 antibody | |
PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
MX2019001977A (en) | Methods and compositions for treating multiple sclerosis and related disorders. | |
IL247586A0 (en) | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer | |
MX2021011799A (en) | Semaphorin-4d antagonists for use in cancer therapy. | |
HK1258235A1 (en) | Inhibitors of pi3k p-delta 110 for use in delivery of viruses in the treatment of cancer | |
MX2016010948A (en) | Compositions and methods for identifying b cell malignancies responsive to b cell depleting therapy. | |
NZ745950A (en) | Methods and compositions for treating multiple sclerosis and related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14762629 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14762629 Country of ref document: EP Kind code of ref document: A2 |